Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study

Escrivá-de-Romani, S; Cejalvo, JM; Alba, E; Friedmann, J; Rodríguez-Lescure, A; Savard, MF; Pezo, RC; Gion, M; Ruiz-Borrego, M; Hamilton, E; Pluard, T; Webster, M; Beeram, M; Linden, H; Saura, C; Shpektor, D; Salim, B; Harvey, P; Hurvitz, SA – 2025 –...